Epidemiology of Carbapenemase-producing Bacteria in a Swiss Tertiary Care Hospital

ConditionInfections With CPB

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorUniversity Hospital, Basel, Switzerland

About this trial

This retrospective and prospective study is to investigate the incidence of Carbapenemase-producing bacteria (CPB) at the University Hospital Basel, the time to detection of CPB and to initiation of infection control measures, the risk factors associated with carriage of CPB, type and duration of previously administrated antibiotic medication, antibiotic treatment, as well as to assess the outcomes of the affected patients.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients with detection of carbapenemase-producing bacteria from January 1st , 2008 until December 31st , 2028

Disqualifiers

Patients with documented refusal of subsequent use of their data

Trial population

Patients treated in the in- or outpatient setting at the University Hospital Basel with detection of carbapenemase-producing bacteria in any screening or clinical sample from January 1st , 2008 until December 31st , 2028

Trial design

Design model

Cohort

Time perspective

Other

Treatments tested in this trial

data collection for demographic data
Other intervention
data collection for demographic data (age, gender, hospital admission and discharge date, length of stay, hospitalization prior to current hospital stay (acute care facilities, long-term healthcare centres, nursing homes), discharge destination, outcome, cause of death, travel history, previous exposure to antibiotics and proton pump Inhibitors)
data collection for clinical data
Other intervention
data collection for clinical data (comorbidities, Charlson Comorbidity Index, immunosuppressive treatment, date of diagnosis of CPB, days between hospital admission and diagnosis of CPB, type of consecutive infection, indwelling vascular hardware, urinary catheterization, surgical therapies)
data collection for treatment data
Other intervention
data collection for treatment data (antibiotic therapy, immunosuppressive therapy, concomitant medication)
data collection for microbiological data
Other intervention
data collection for microbiological data (species of CPB, type of sample, date of sample, history of colonization or infection with any antibiotic resistant pathogen)

Treatment groups

No treatment groups listed